spencerĀ® Technology in Clinical Research Offers Greater Adherence to Trial Drugs, Lower Costs

FOR IMMEDIATE RELEASE:  Non-adherence in clinical trials drives operational costs significantly higher96% of spencer users are adherent; and reducing non-adherence in trials by just 1% can reduce costs by up to $300KPatient-reported outcomes (PRO) gathered through spencer offer pharma, regulators and payers a new way to study the impact of an investigational drug on a … Continue reading spencerĀ® Technology in Clinical Research Offers Greater Adherence to Trial Drugs, Lower Costs